Aberrant methylation of LINE-1, SLIT2, MAL and IGFBP7 in non-small cell lung cancer

Oncology Reports

Volumn 29, Issue 4, 2013, Pages 1308-1314

  Suzuki, Makot ^a   Shiraishi, Kenji ^a   Eguchi, Ayami ^a   Ikeda, Koei ^a   Mori, Takeshi ^a   Yoshimoto, Kentaro ^a   Ohba, Yasuomi ^a   Yamada, Tatsuya ^a   Ito, Takaaki ^b   Baba, Yoshifumi ^c   Baba, Hideo ^c  

^a KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^b Pathology and Experimental Medicine   (Japan)

^c KUMAMOTO UNIVERSITY   (Japan)

Author keywords

IGFBP7; LINE 1; MAL; Methylation; Pyrosequencing; SLIT2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; MYELIN AND LYMPHOCYTE PROTEIN;

ADULT; ARTICLE; CANCER CELL; CONTROLLED STUDY; DNA METHYLATION; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INSULIN LIKE GROWTH FACTOR BINDING PROTEIN 7 GENE; LONG INTERSPERSED NUCLEOTIDE ELEMENT 1 GENE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MYELIN AND LYMPHOCYTE PROTEIN GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PYROSEQUENCING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SLIT HOMOLOG 2 GENE; SMOKING;

CARCINOMA, NON-SMALL-CELL LUNG; CELL TRANSFORMATION, NEOPLASTIC; DNA METHYLATION; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LONG INTERSPERSED NUCLEOTIDE ELEMENTS; LUNG NEOPLASMS; MYELIN AND LYMPHOCYTE-ASSOCIATED PROTEOLIPID PROTEINS; NERVE TISSUE PROTEINS;

EID: 84874725616     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2266     Document Type: Article

References (33)

1. Takai D and Jones PA: Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proc Natl Acad Sci USA 99: 3740-3745, 2002.
2. Suzuki M and Yoshino I: Aberrant methylation in non-small cell lung cancer. Surg Today 40: 602-607, 2010.
3. Gaudet F, Hodgson JG, Eden A, et al: Induction of tumors in mice by genomic hypomethylation. Science 300: 489-492, 2003.
4. Herman JG, Graff JR, Myohanen S, Nelkin BD and Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93: 9821-9826, 1996.
5. Lo YM, Wong IH, Zhang J, Tein MS, Ng MH and Hjelm NM: Quantitative analysis of aberrant p16 methylation using real-time quantitative methylation-specific polymerase chain reaction. Cancer Res 59: 3899-3903, 1999.
6. Xiong Z and Laird PW: COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res 25: 2532-2534, 1997.
7. Suzuki M, Toyooka S, Shivapurkar N, et al: Aberrant methylation profile of human malignant mesotheliomas and its relationship to SV40 infection. Oncogene 24: 1302-1308, 2005.
8. Takahashi T, Shivapurkar N, Riquelme E, et al: Aberrant promoter hypermethylation of multiple genes in gallbladder carcinoma and chronic cholecystitis. Clin Cancer Res 10: 6126 6133, 2004.
9. Tamura H, Suzuki M, Moriya Y, et al: Aberrant methylation of N-methyl-D-aspartate receptor type 2B (NMDAR2B) in non-small cell carcinoma. BMC Cancer 11: 220, 2011.
10. Tian L, Suzuki M, Nakajima T, et al: Clinical significance of aberrant methylation of prostaglandin E receptor 2 (PTGER2) in nonsmall cell lung cancer: association with prognosis, PTGER2 expression, and epidermal growth factor receptor mutation. Cancer 113: 1396-1403, 2008.
11. Ronaghi M: Pyrosequencing sheds light on DNA sequencing. Genome Res 11: 3-11, 2001.
12. Sepulveda AR, Jones D, Ogino S, et al: CpG methylation analysis-current status of clinical assays and potential applications in molecular diagnostics: a report of the Association for Molecular Pathology. J Mol Diagn 11: 266-278, 2009.
13. Iwagami S, Baba Y, Watanabe M, et al: Pyrosequencing assay to measure LINE-1 methylation level in esophageal squamous cell carcinoma. Ann Surg Oncol 19: 2726-2732, 2011.
14. Yamaji H, Iizasa T, Koh E, et al: Correlation between inter¬leukin 6 production and tumor proliferation in non-small cell lung cancer. Cancer Immunol Immunother 53: 786-792, 2004.
15. Suzuki M, Sunaga N, Shames DS, Toyooka S, Gazdar AF and Minna JD: RNA interference-mediated knockdown of DNA methyltransferase 1 leads to promoter demethylation and gene re-expression in human lung and breast cancer cells. Cancer Res 64: 3137-3143, 2004.
16. Baba Y, Huttenhower C, Nosho K, et al: Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol Cancer 9: 125, 2010.
17. Yoshida K, Yatabe Y, Park JY, et al: Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer. J Thorac Oncol 2: 22-28, 2007.
18. Moses LE, Shapiro D and Littenberg B: Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 12: 1293-1316, 1993.
19. Saito K, Kawakami K, Matsumoto I, Oda M, Watanabe G and Minamoto T: Long interspersed nuclear element 1 hypomethyl¬ation is a marker of poor prognosis in stage IA non-small cell lung cancer. Clin Cancer Res 16: 2418-2426, 2010.
20. Dallol A, Da Silva NF, Viacava P, et al: SLIT2, a human homologue of the Drosophila Slit2 gene, has tumor suppressor activity and is frequently inactivated in lung and breast cancers. Cancer Res 62: 5874-5880, 2002.
21. Kwon YJ, Lee SJ, Koh JS, et al: Genome-wide analysis of DNA methylation and the gene expression change in lung cancer. J Thorac Oncol 7: 20-33, 2012.
22. Suzuki M, Wada H, Yoshino M, et al: Molecular characteriza¬tion of chronic obstructive pulmonary disease-related non-small cell lung cancer through aberrant methylation and alterations of EGFR signaling. Ann Surg Oncol 17: 878-888, 2010.
23. Puertollano R, Martin-Belmonte F, Millan J, et al: The MAL proteolipid is necessary for normal apical transport and accurate sorting of the influenza virus hemagglutinin in Madin-Darby canine kidney cells. J Cell Biol 145: 141-151, 1999.
24. Mimori K, Shiraishi T, Mashino K, et al: MAL gene expres¬sion in esophageal cancer suppresses motility, invasion and tumorigenicity and enhances apoptosis through the Fas pathway. Oncogene 22: 3463-3471, 2003.
25. Lind GE, Ahlquist T, Kolberg M, et al: Hypermethylated MAL gene-A silent marker of early colon tumorigenesis. J Transl Med 6: 13, 2008.
26. Buffart TE, Overmeer RM, Steenbergen RD, et al: MAL promoter hypermethylation as a novel prognostic marker in gastric cancer. Br J Cancer 99: 1802-1807, 2008.
27. Overmeer RM, Henken FE, Bierkens M, et al: Repression of MAL tumour suppressor activity by promoter methylation during cervical carcinogenesis. J Pathol 219: 327-336, 2009.
28. Ruan W, Xu E, Xu F, et al: IGFBP7 plays a potential tumor suppressor role in colorectal carcinogenesis. Cancer Biol Ther 6: 354-359, 2007.
29. Vizioli MG, Sensi M, Miranda C, et al: IGFBP7: an oncosuppressor gene in thyroid carcinogenesis. Oncogene 29: 3835-3844, 2010.
30. Mutaguchi K, Yasumoto H, Mita K, et al: Restoration of insulin-like growth factor binding protein-related protein 1 has a tumor-suppressive activity through induction of apoptosis in human prostate cancer. Cancer Res 63: 7717-7723, 2003.
31. Smith P, Nicholson LJ, Syed N, et al: Epigenetic inactivation implies independent functions for insulin-like growth factor binding protein (IGFBP)-related protein 1 and the related IGFBPL1 in inhibiting breast cancer phenotypes. Clin Cancer Res 13: 4061-4068, 2007.
32. Ye F, Chen Y, Knosel T, et al: Decreased expression of insulin-like growth factor binding protein 7 in human colorectal carcinoma is related to DNA methylation. J Cancer Res Clin Oncol 133: 305-314, 2007.
33. Chen Y, Cui T, Knosel T, Yang L, Zoller K and Petersen I: IGFBP7 is a p53 target gene inactivated in human lung cancer by DNA hypermethylation. Lung Cancer 73: 38-44, 2011.